The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
 
Makoto Endo
Honoraria - Eisai; Taisho Pharmaceutical Holdings; Taisho Toyama Pharma
 
Kazuhiro Tanaka
Honoraria - Eisai; Novartis; Taiho Pharmaceutical
 
Yoshihiro Matsumoto
No Relationships to Disclose
 
Hiroaki Hiraga
Honoraria - Eisai; Hisamitsu Pharmaceutical; Kaken Pharmaceutical; Novartis; Taiho Pharmaceutical
Research Funding - Lilly Japan (Inst)
 
Shintaro Iwata
No Relationships to Disclose
 
Satoshi Tsukushi
No Relationships to Disclose
 
Munenori Watanuki
Travel, Accommodations, Expenses - Eisai
 
Toru Akiyama
No Relationships to Disclose
 
Tsukasa Yonemoto
No Relationships to Disclose
 
Robert Nakayama
No Relationships to Disclose
 
Keisuke Ae
No Relationships to Disclose
 
Hiroyuki Kawashima
No Relationships to Disclose
 
Hiroyuki Tsuchiya
No Relationships to Disclose
 
Hirohisa Katagiri
No Relationships to Disclose
 
Akihito Nagano
No Relationships to Disclose
 
Satoshi Takenaka
No Relationships to Disclose
 
Tomoko Kataoka
No Relationships to Disclose
 
Ryunosuke Machida
No Relationships to Disclose
 
Haruhiko Fukuda
Honoraria - Chugai Pharma
 
Toshifumi Ozaki
No Relationships to Disclose